Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Stocks making big moves yesterday: Cadence Design Systems, JFrog, Lucid, Ulta, and Biogen

StockStory - StockStory - Tue Apr 21, 8:00AM CDT
CDNS

CDNS Cover Image

Check out the companies making headlines yesterday:

Cadence Design Systems (NASDAQ:CDNS): Electronic design automation company Cadence Design Systems (NASDAQ:CDNS) rose by 2.1% on Monday after investors continued to buy the dip despite renewed geopolitical jitters as the U.S.-Iran ceasefire came under doubt following the seizure of the Iranian vessel Touska. See our full article here.

Is now the time to buy Cadence Design Systems? Access our full analysis report here, it's free.

JFrog (NASDAQ:FROG): Software supply chain platform JFrog (NASDAQ:FROG) rose by 2.2% on Monday after investors continued to buy the dip despite renewed geopolitical jitters as the U.S.-Iran ceasefire came under doubt following the seizure of the Iranian vessel Touska. See our full article here.

Is now the time to buy JFrog? Access our full analysis report here, it's free.

Lucid (NASDAQ:LCID): Luxury electric car manufacturer Lucid (NASDAQ:LCID) fell by 5.6% on Monday after the stock hit a new all-time low as traders assessed recent financing and a leadership transition. See our full article here.

Is now the time to buy Lucid? Access our full analysis report here, it's free.

Ulta (NASDAQ:ULTA): Beauty, cosmetics, and personal care retailer Ulta Beauty (NASDAQ:ULTA) rose by 3.3% on Monday after Jefferies upgraded the stock to Buy from Hold, citing renewed strength and consumer engagement in the cosmetics sector. See our full article here.

Is now the time to buy Ulta? Access our full analysis report here, it's free.

Biogen (NASDAQ:BIIB): Biotech company Biogen (NASDAQ:BIIB) rose by 3.6% on Monday after the company received an analyst upgrade from Wells Fargo and announced it acquired exclusive worldwide rights for the drug candidate felzartamab. See our full article here.

Is now the time to buy Biogen? Access our full analysis report here, it's free.

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).